Pfizer and Moderna are diligently working to launch new products and turn things around. And if their strategies pan out, ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines company navigated a “challenging regulatory and business environment.” ...

VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.

In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk melanoma, while the FDA granted expedited review and an August 5, 2026 ...

BlackRock Health Sciences Trust II trades at a 12.76% discount to NAV, near its deepest 1-year discount, but faces risks.

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Alumis Inc., with a price target of $38.00. According to TipRanks, Flynn is a 5-star analyst with an average ...

In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day. This change lagged the S&P 500's daily loss of 1.51%. On the other hand, the Dow registered ...

This oversold FTSE 100 value stock is near the top of many experts’ buy lists this year, offering a potentially explosive ...

S&P 500, SPDR® S&P 500® ETF Trust, SanDisk Corporation, Texas Pacific Land Corp. Read 's Market Analysis on Investing.com ...

CytomX expects to use the net proceeds from this offering for the continued development of Varseta-M and other pipeline programs. CytomX expects to use any remaining net proceeds from this offering ...

Executive chairman Patrick Soon-Shiong highlighted early immune activation data from an Anktiva study. ・Anktiva was also added to Macau’s drug list and included in updated NCCN guidelines for ...